They currently support research areas including: Optimizing oral polio vaccine efficacy, Optimizing oral polio vaccine delivery, Developing affordable inactivated polio vaccine, Managing risks associated with vaccine-derived polioviruses and vaccine-associated paralytic polio (including Oral Polio Vaccine (OPV) cessation), Antivirus, Polio diagnostics and Surveillance research.[4]
Their efforts were not wasted when it was reported that the "World is ready for OPV2 cessation" in 11 December 2014. At the October 2014 meeting, the Strategic Advisory Group of Experts on immunization (SAGE) - the independent body advising the World Health Organization(WHO) on immunization - concluded that preparations for the Oral Polio Vaccine type 2 (OPV2) withdrawal in early 2016 are on track. According to the article, this conclusion is of utmost importance in the success of Polio Eradication & Endgame Strategic Plan 2013-2018. The main aim was to remove the risk of cVDPV2 emerging by switching from trivalent OPV(containing type 1,2 and 3 serotypes) to bivalent OPV (containing only type 1 and 3 serotypes) in routine immunization programmes since cVDPV2 had emerged in several countries in 2014 despite the wild poliovirus type 2 being eradicated since 1999. [5]
But what does this mean?
There are plans to introduce inactivated polio vaccines (IPV) into the routine systems of 119 countries globally by the end of the year 2015. This marks one of the largest globally coordinated vaccine introduction projects in history. In order for this ambitious feat to be accomplished, all those countries will need to switch vaccines in the immunization programs carried out in April 2016. In a 2 week switch period, countries will decide on a National Switch Day in order to minimize the risk of a country continuing to use the trivalent OPV and inadvertently re-infecting other neighboring countries no longer using that particular vaccine.
The Global Polio Eradication Initiative is working closely with countries, regions, partners and manufacturers to ensure the vaccine supply is properly managed so as to gradually reduce the stck of trivalent OPVs that will eventually no longer be in use in the near future. This is to ensure that the trivalent OPVs remains in stock until the last day , countries of course would need to be cautious and arrange for service points as well as the proper disposal of stock. A one week buffer supply will be calculated and maintained to ensure that no child remains unimmunized during the switch week. [5]
As of 21 July 2015, WHO had put up a notice seeking consultants for the OPV expanded project in preparation for switch day. To see the application form, click Here.
[4] [http://www.polioeradication.org/Research.aspx] Research. (n.d.). Retrieved July 30, 2015.
No comments:
Post a Comment